NCT05327517Recruiting
Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
Surgery Versus Definitive Chemoradiotherapy for Resectable Cervical Esophageal Squamous Cell Carcinoma: A Prospective Multicenter Open-Label Clinical Trial
Source: ClinicalTrials.gov · Last updated 14 Apr 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To compare surgery with definitive chemoradiotherapy for patients with resectable cervical esophageal squamous cell carcinoma.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 192 (estimated)
- First submitted
- 7 Apr 2022
- Start date
- 10 Apr 2022
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05327517
What you commit to
- Study type: Interventional
- Planned participants: 192
- From 10 Apr 2022 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Without other malignancies;
- With mental diseases;
- With hemorrhagic disease;
- Has a history of allergy to paclitaxel or cisplatin
Other
- Inoperable patients;
- Pregnant or lactating women;
Who the study is looking for
- Patients with resectable cervical esophageal squamous cell carcinoma (cT1b-T4aN0-3M0);
- Cervical esophageal cancers spreads upwards to involve the hypopharynx and downwards to involve the thoracic esophagus can also be included;
- Aged 18-75 years;
- Without any contraindication of operation;
- Hemoglobin \>=90 g/L; Leukocytes \>=4.0x10\^9/L; Absolute neutrophil count \>=1.5x10\^9/L; Platelet \>=100x10\^9/L;Total bilirubin \<=1.5 ULN; ALT \<=2.5 ULN; AST \<=2.5 ULN; Serum creatinine \<=1.5 ULN or creatinine clearance rate \>=50 mL/min (Cocheroft-Gault);INR \<=1.5 ULN; APTT \<=1.5 ULN;
- Without other malignancies;
- Expected R0 resection;
- ECOG PS 0-1;
- Volunteered to participate in the study, signed the informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hospital, Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.